The notices it replaced
- Reissues: PAR-24-088 Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
- 2 steps back: PAR-21-029 Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
- 3 steps back: PAR-17-336 Discovery of in vivo Chemical Probes for Novel Brain Targets (R01)
- 4 steps back: PAR-14-279 Discovery of in vivo Chemical Probes (R01)
- 5 steps back: PAR-12-060 Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01)
Who won it before
58 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $38,291,892 in first-year total cost, median $581,982.
Most frequent study sections
- Special Emphasis Panel[ZRG1 MDCN-C (58)]38
- Drug Discovery for the Nervous System Study Section[DDNS]12
- Drug Discovery and Molecular Pharmacology B Study Section[DMPB]4
- Special Emphasis Panel[ZRG1-MDCN-C(58)R]2
- Molecular and Cellular Neuropharmacology Study Section [MCNP]1
Most frequent institutions
- VANDERBILT UNIVERSITY7
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE4
- UNIV OF NORTH CAROLINA CHAPEL HILL4
- MASSACHUSETTS GENERAL HOSPITAL3
- RESEARCH TRIANGLE INSTITUTE3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Regulation of metabotropic glutamate receptor activity by protein/protein interactions1R01MH136164-01A1 · under PAR-24-088 | NISWENDER, COLLEEN M | VANDERBILT UNIVERSITY, TN | $396,250 | MCNP |
| 2024 | Optimization of a potent and cell active CK2 chemical probe for Alzheimer's disease therapy1R56AG084730-01A1 · under PAR-21-029 | AXTMAN, ALISON DONNELLY | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $833,173 | DMPB |
| 2024 | Development of sterol carrier protein 2 inhibitors as anxiolytics1R01MH133315-01A1 · under PAR-21-029 | CUNNINGHAM, CHRISTOPHER WHILLARD, CECILIA JLIEDHEGNER, ELIZABETH S | MEDICAL COLLEGE OF WISCONSIN, WI | $679,286 | DMPB |
| 2024 | In Vivo Probes of Mas1 Receptor1R01MH135136-01 · under PAR-21-029 | MAITRA, RANGANRUNYON, SCOTT P | RESEARCH TRIANGLE INSTITUTE, NC | $636,641 | DMPB |
| 2023 | BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research1RF1AG081195-01 · under PAR-21-029 | WANG, CHANGNINGZHANG, CAN MARTIN | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,442,345 | DDNS |
| 2023 | Probing neuroinflammation in Alzheimer's disease with NLRP3 PET radiotracers1RF1AG076912-01A1 · under PAR-21-029 | ZHANG, SHIJUN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $1,889,973 | DDNS |
| 2023 | Small-molecule probes for augmenting D5 receptor signaling1R01MH132019-01 · under PAR-21-029 | BARROW, JAMESCARR, GREGORY V | LIEBER INSTITUTE, INC., MD | $837,713 | DDNS |
| 2023 | Probing brain circuit and behavior with protein:protein interaction modulators1R01MH132226-01 · under PAR-21-029 | LAEZZA, FERNANDAZHOU, JIA | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $824,232 | DDNS |
| 2023 | Structure-based Design of Selective Serotonin Biased Agonists as Chemical Probes for Psychedelic Potential1R01MH133849-01 · under PAR-21-029 | MCCORVY, JOHN D | MEDICAL COLLEGE OF WISCONSIN, WI | $530,972 | DMPB |
| 2022 | Development of in vivo probes to study the function of TRIP8b in cognition1R56MH128747-01A1 · under PAR-21-029 | CHETKOVICH, DANE MSCHILTZ, GARY E | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $847,526 | DDNS |
| 2021 | Development of PET imaging probes for ROCK21R01AG069921-01 · under PAR-17-336 | CAI, ZHENGXIN | YALE UNIVERSITY, CT | $836,532 | DDNS |
| 2021 | Characterization of an 18F COX-2 PET ligand for in vivo brain imaging1R01AG070042-01 · under PAR-17-336 | PRABHAKARAN, JAYA | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $476,564 | DDNS |
| 2020 | Novel allosteric activation of nicotinamide rescue1RF1AG067771-01 · under PAR-17-336 | THATCHER, GREGORY R. J | UNIVERSITY OF ARIZONA, AZ | $2,264,368 | DDNS |
| 2020 | Small molecule antagonist probes for the relaxin-3/RXFP3 system1R01AA028255-01 · under PAR-17-336 | BESHEER, JOYCEJIN, CHUNYANG | RESEARCH TRIANGLE INSTITUTE, NC | $594,334 | DDNS |
| 2019 | Lead optimization of novel CRFBP-CRFR2 complex modulators for alcohol use disorder1R01AA026589-01A1 · under PAR-17-336 | SHEFFLER, DOUGLAS J | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $865,843 | DDNS |
| 2019 | In vivo Probe for ionotropic glutamate signaling system: AMPA receptors1R01MH120197-01 · under PAR-17-336 | LIANG, STEVEN H | MASSACHUSETTS GENERAL HOSPITAL, MA | $719,969 | DDNS |
| 2019 | Evaluation Of Trk Probes In Models For Dry Eye Disease1R01EY029695-01 · under PAR-17-336 | BURGESS, KEVIN | TEXAS A&M UNIVERSITY, TX | $489,413 | DDNS |
| 2018 | Targeting RIPK3 in Age-Related Inflammation and Injury1R56AG058642-01 · under PAR-14-279 | BALACHANDRAN, SIDDHARTHCUNY, GREGORY DDEGTEREV, ALEXEI | TUFTS UNIVERSITY BOSTON, MA | $648,995 | ZRG1 |
| 2018 | Development of NLRP3 inflammasome inhibitors towards Alzheimer's disease1R01AG058673-01 · under PAR-14-279 | SUN, DONGWANG, XIANG-YANG SHAWNZHANG, SHIJUN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $609,347 | ZRG1 |
| 2018 | Expanding the Chemical Biology of K2P Channels with Selective Cellular and In vivo Probes1R01MH116278-01 · under PAR-14-279 | MINOR, DANIEL LRENSLO, ADAM R | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $488,166 | ZRG1 |
| 2018 | DISCOVERY OF IN VIVO CHEMICAL PROBES FOR POLYCOMB CBX DOMAINS1R01CA218392-01A1 · under PAR-14-279 | FRYE, STEPHEN VERNON | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $456,482 | ZRG1 |
| 2017 | Creation of in vivo active chemical probes for CAMKK2 to treat cancer1R01CA218442-01 · under PAR-14-279 | DREWRY, DAVID HAROLD | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $691,617 | ZRG1 |
| 2017 | Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy1R01CA214567-01 · under PAR-14-279 | BUCKANOVICH, RONALD JLARSEN, SCOTT D | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $636,181 | ZRG1 |
| 2017 | Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation1R01CA216863-01 · under PAR-14-279 | GERSON, STANTON L.MARKOWITZ, SANFORD D.READY, JOSEPH M | UT SOUTHWESTERN MEDICAL CENTER, TX | $520,706 | ZRG1 |
| 2017 | USP7 inhibitors for the treatment of multiple myeloma1R01CA211681-01 · under PAR-14-279 | BUHRLAGE, SARA J | DANA-FARBER CANCER INST, MA | $504,721 | ZRG1 |
| 2017 | Development of a Selective Metabotropic Glutamate Receptor 7 Allosteric Modulator Probe1R01MH113543-01 · under PAR-14-279 | LINDSLEY, CRAIGNISWENDER, COLLEEN M | VANDERBILT UNIVERSITY, TN | $400,356 | ZRG1 |
| 2017 | Non-Covalent Nrf2 Activators for the Treatment of Chronic Wounds1R01AR069541-01A1 · under PAR-14-279 | MOORE, TERRY WILLIAM | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $347,552 | ZRG1 |
| 2016 | Discovery of probes that enhance expression of the neuroprotective protein Klotho1R56AG051638-01A1 · under PAR-14-279 | ABRAHAM, CARMELA RHODGETTS, KEVIN | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $855,556 | ZRG1 |
| 2016 | Lead optimization of novel ML-IAP antagonists to treat lung cancer1R01CA195227-01A1 · under PAR-14-279 | COSFORD, NICHOLAS DAVIDFINLAY, DARREN | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $808,701 | ZRG1 |
| 2016 | NPQ/Spexin the Endogenous Ligand for the Galanin Receptor 31R01DA040882-01A1 · under PAR-14-279 | OZAWA, AKIHIKOTOLL, LAWRENCE R | TORREY PINES INST FOR MOLECULAR STUDIES, FL | $742,361 | ZRG1 |
| 2016 | Optimization of glucocorticoid receptor (GR) passive antagonists for the treatment of post-traumatic stress disorder (PTSD)1R01MH109655-01 · under PAR-14-279 | JACKSON, MICHAELPINKERTON, ANTHONY BRUCE | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $611,804 | ZRG1 |
| 2016 | Discovery of in vivo small molecules for hearing protection against cisplatin and noise1R01DC015444-01 · under PAR-14-279 | ZUO, JIAN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $595,909 | ZRG1 |
| 2016 | Optimization of S1P3 antagonists for fibrotic disease1R01AR069877-01 · under PAR-14-279 | ROSEN, HUGH | SCRIPPS RESEARCH INSTITUTE, THE, CA | $592,901 | ZRG1 |
| 2016 | ERRgamma Agonists to Treat Muscular Dystrophy1R01AR069280-01A1 · under PAR-14-279 | BURRIS, THOMAS PWALKER, JOHN K. | SAINT LOUIS UNIVERSITY, MO | $580,666 | ZRG1 |
| 2016 | Microbiome-Targeted Probes to Eliminate Chemotherapy-Induced GI Toxicity1R01CA207416-01 · under PAR-14-279 | REDINBO, MATTHEW R | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $552,404 | ZRG1 |
| 2016 | Development of an mGlu2/4 heterodimer-selective allosteric modulator1R01MH108498-01 · under PAR-14-279 | LINDSLEY, CRAIGNISWENDER, COLLEEN M | VANDERBILT UNIVERSITY, TN | $516,805 | ZRG1 |
| 2016 | Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer1R01CA206493-01 · under PAR-14-279 | GRIFFIN, PATRICK ROBERTKAMENECKA, THEODORE M | SCRIPPS FLORIDA, FL | $439,200 | ZRG1 |
| 2016 | Optimization of ERRg-specific ligands as in vivo Chemical Probes1R01HD087046-01 · under PAR-14-279 | GRIFFIN, PATRICK ROBERTKAMENECKA, THEODORE M | SCRIPPS FLORIDA, FL | $398,400 | ZRG1 |
| 2015 | Discovery of Chemical Probes for RNA-Binding Protein Host Defense Factors1R01GM110119-01A1 · under PAR-12-060 | SMITH, HAROLD C | OYAGEN, INC., NY | $601,514 | ZRG1 |
| 2015 | Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammation1R01AR068436-01 · under PAR-14-279 | LIOTTA, LANCE ALLEN | GEORGE MASON UNIVERSITY, VA | $595,160 | ZRG1 |
| 2015 | Development of a Novel Inducer for EBV Lytic Therapy1R01CA193624-01 · under PAR-12-060 | KENNEY, SHANNON CELESTELIEBERMAN, PAUL M.SALVINO, JOSEPH M | WISTAR INSTITUTE, PA | $591,954 | ZRG1 |
| 2015 | Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator1R01MH107399-01 · under PAR-14-279 | HOPKINS, COREY R.WEAVER, C DAVIDWICKMAN, KEVIN D | VANDERBILT UNIVERSITY, TN | $583,297 | ZRG1 |
| 2015 | Small molecule CXCR4 modulators as molecular probes for studying AML1R01CA189074-01A1 · under PAR-14-279 | MILLER, RICHARD JPLATANIAS, LEONIDAS C.SCHILTZ, GARY E | NORTHWESTERN UNIVERSITY, IL | $529,121 | ZRG1 |
| 2015 | Partial Agonists at Estrogen Receptor alpha for Breast Cancer Therapy1R01CA188017-01A1 · under PAR-12-060 | THATCHER, GREGORY R. J | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $485,489 | ZRG1 |
| 2015 | Development of RORbeta-selective modulators as in vivo probes1R01MH108173-01 · under PAR-14-279 | GRIFFIN, PATRICK ROBERTKAMENECKA, THEODORE M | SCRIPPS FLORIDA, FL | $480,000 | ZRG1 |
| 2015 | Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapy1R01NS088437-01A1 · under PAR-12-060 | LI, CHENGLONGYANG, YUHONG | OHIO STATE UNIVERSITY, OH | $471,114 | ZRG1 |
| 2015 | Chemical Probes for In Vivo Fibrin Imaging1R01CA197401-01 · under PAR-14-279 | ZHANG, ZHAODA | MASSACHUSETTS GENERAL HOSPITAL, MA | $466,961 | ZRG1 |
| 2015 | Discovery of mAChR5 Modulators for Use in Rodent Models of Drug Addiction1R01DA037207-01A1 · under PAR-12-060 | JONES, CARRIE KIMBERLYLINDSLEY, CRAIG | VANDERBILT UNIVERSITY, TN | $353,142 | ZRG1 |
| 2014 | Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN1R01CA188694-01 · under PAR-12-060 | COSFORD, NICHOLAS DAVIDSMITH, JEFFREY W | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $755,282 | ZRG1 |
| 2014 | Inhibition of the Rho/MRTF/SRF Pathway as a New Treatment for Systemic Sclerosis1R01AR066049-01 · under PAR-12-060 | LARSEN, SCOTT D | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $655,452 | ZRG1 |
| 2014 | Development and Application of Selective Covalent Cdk7 Inhibitors1R01CA179483-01A1 · under PAR-12-060 | GRAY, NATHANAEL SCHIANDERMITSIADES, CONSTANTINE S. | DANA-FARBER CANCER INST, MA | $505,961 | ZRG1 |
| 2014 | Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes1R01EY023725-01A1 · under PAR-12-060 | ANTONETTI, DAVID | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $499,870 | ZRG1 |
| 2014 | Optimization of non-peptide probes for the NPFF receptor system1R01DA034777-01A1 · under PAR-12-060 | MCCURDY, CHRISTOPHER R | UNIVERSITY OF MISSISSIPPI, MS | $498,705 | ZRG1 |
| 2014 | Discovery of Potent 12-Lipoxygenase Inhibitors of Platelet Activation1R01AG047986-01 · under PAR-12-060 | HOLMAN, THEODORE R | UNIVERSITY OF CALIFORNIA SANTA CRUZ, CA | $496,455 | ZRG1 |
| 2014 | Small molecules modulating RNA-binding protein Msi11R01CA178831-01A1 · under PAR-12-060 | AUBE, JEFFREYNEUFELD, KRISTI LXU, LIANG | UNIVERSITY OF KANSAS LAWRENCE, KS | $432,491 | ZRG1 |
| 2014 | In vivo probes for the APJ receptor.1R01HD079547-01A1 · under PAR-12-060 | MAITRA, RANGANRUNYON, SCOTT P | RESEARCH TRIANGLE INSTITUTE, NC | $427,829 | ZRG1 |
| 2014 | Optimization of modulators of Gbg-SNARE interaction1R01MH101679-01A1 · under PAR-12-060 | HAMM, HEIDI ESTAUFFER, SHAUN R | VANDERBILT UNIVERSITY, TN | $400,752 | ZRG1 |
| 2014 | Allosteric modulators of the glucagon-like peptide-1 receptor1R01GM106232-01A1 · under PAR-12-060 | DANIELS, JOHN SCOTTLINDSLEY, CRAIGNISWENDER, KEVIN D | VANDERBILT UNIVERSITY, TN | $297,379 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.